GET DAILY SIGNALSTempest Therapeutics (TPST): Could Shares Reach the $1.00 Level With +160% Upside?
Key Takeaways
- The central target of $1 used here is not an analyst consensus; with only one current, attributable price target, it reflects a publicly discussed $1.00 psychological and Nasdaq listing-compliance threshold for sub-dollar stocks.
- Tempest Therapeutics, Inc. (TPST) closed near $0.38, meaning a move to $1 would require upside of roughly 160% — a very large move for a cash-constrained clinical-stage biotech.
- The sole current analyst target is $7 from H.C. Wainwright (Joseph Pantginis), lowered from $11 on September 24, 2026; there is no meaningful multi-analyst average to rely on.
- Supporting factors include a Phase 3-ready lead asset (amezalpat) with prior positive Phase 2 liver-cancer data and a newly added CAR-T pipeline.
- Key risks are acute cash pressure, financing overhang and dilution, early-stage pipeline transition, and sub-dollar trading with listing-compliance exposure.
- You can explore more on the ticker's Major News and Today's Price Move, plus its Forecast and Earnings pages.
- Interested readers can also explore Trending AI Robots for automated market-monitoring ideas.
Understanding the $1 Target
Tempest Therapeutics is a stock, not an ETF, and its analyst coverage has thinned to a single current, verifiable target. H.C. Wainwright's Joseph Pantginis maintained a Buy rating but cut his price target to $7 from $11 on September 24, 2026. Because one target does not form a meaningful aggregate, this article does not present an "average analyst price target." Instead, the $1.00 figure reflects a price objective that is widely discussed in public market commentary for sub-dollar names: the Nasdaq Capital Market's $1.00 minimum bid price threshold, a listing-compliance level and round-number psychological milestone. That level is roughly 160% above the latest price, satisfying the requirement that a fallback target be meaningful but not arbitrarily distant. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of early November 2026, Tempest Therapeutics (TPST) traded near $0.38, with a 52-week range of roughly $0.37 to $10.33 and a market capitalization around $7.6 million. Reaching $1.00 would require an advance of approximately 160%, a very large move. The company is a clinical-stage oncology developer that has repositioned from its historical lead program, amezalpat (TPST-1120), toward an in vivo CAR-T strategy acquired from Factor Bioscience in early 2026. With total cash reported near $780,000 and a trailing twelve-month net loss of about $40 million, the near-term path depends less on valuation multiples and more on financing, partnerships, and clinical execution.
What Could Support a Move Toward the Target
Amezalpat remains Phase 3-ready for first-line hepatocellular carcinoma (HCC, the most common form of liver cancer), backed by earlier randomized Phase 2 data showing a six-month overall survival benefit and an objective response rate favoring the combination arm. It has fast-track and orphan drug designations and a collaboration with Roche. The newly acquired dual-targeting CAR-T assets, including the clinical-stage TPST-2003 program in relapsed or refractory multiple myeloma, broaden the pipeline. Any successful financing, strategic partnership, or positive clinical or regulatory update could materially re-rate a stock with such a depressed market capitalization. From what I see, this is important because clinical momentum often drives re-ratings in names like this.
What Could Prevent the Target From Being Reached
The principal obstacle is capital. With minimal cash and recurring losses, Tempest will likely need additional funding, and further raises could dilute existing holders. The company implemented a 1-for-13 reverse stock split in April 2025, and sub-dollar trading introduces ongoing Nasdaq minimum-bid compliance risk. The pivot toward an unproven, early-stage cell-therapy platform raises scientific and execution uncertainty, while reports that the company struggled to secure a partner or buyer to fund amezalpat's late-stage development have weighed on sentiment. Liquidity is thin, making daily price swings pronounced.
Technical Levels and Market Structure
The $1.00 level is the most relevant psychological and compliance threshold, while the 50-day moving average near $0.77 and the 200-day moving average near $1.46 sit above the current price and represent intermediate overhead supply. The 52-week low near $0.37 is the nearest support zone. A sustained break above $1.00 would be a meaningful structural signal, but the stock's severe downtrend and extremely low price leave little near-term technical support below the current level. I’m watching this closely as the technical setup remains fragile.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though the single H.C. Wainwright target of $7 implies a far more optimistic scenario than the $1.00 objective discussed here. Investors should watch for the upcoming earnings report expected in November 2026, financing announcements, updates on the CAR-T pipeline and amezalpat's path forward, any partnership or strategic-transaction news, and Nasdaq listing-compliance developments. A stockholder meeting was reported as adjourned to November 12, 2026, underscoring the near-term governance and financing items in focus.
Monitoring With AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-liquidity name like TPST, this kind of systematic monitoring can help traders spot changing trends, discover opportunities, and manage positions more efficiently than manual chart-watching alone. I find it useful in my own process for staying on top of fast-moving developments in names with limited coverage.
Final Assessment
The question of whether TPST can reach $1 is really a question about survival, financing, and execution rather than near-term earnings power. The $1.00 objective is a psychological and listing-compliance milestone requiring roughly a 160% advance from around $0.38 — a very large move. Support could come from a partnership or capital infusion and from clinical progress across the amezalpat and CAR-T programs, while the overriding risks are cash depletion, dilution, pipeline uncertainty, and sub-dollar trading dynamics. The lone analyst target of $7 signals that institutional coverage sees meaningful upside if the science and funding align, but that target carries enormous uncertainty. Investors should monitor financing, clinical updates, and Nasdaq compliance closely, with no guarantee the stock moves toward any particular level. One thing that stands out is how much hinges on near-term execution in a capital-intensive sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for TPST turns negative, indicating new downward trend
TPST saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 73 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TPST turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 44 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TPST entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPST advanced for three days, in 178 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TPST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.897) is normal, around the industry mean (3.498). P/E Ratio (-0.103) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TPST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals
Industry Biotechnology
Advertisement